Pharmion And MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 And Vidaza(R) In Patients With Relapsed Or Refractory Hodgkin Lymphoma

Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) announced the enrollment of the first patient in a Phase 2 clinical trial (Trial CL002) evaluating MGCD0103, the Companies’ isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Vidaza(R) (azacitidine for injection), Pharmion’s DNA demethylating agent, in patients with relapsed or refractory Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL).

More: continued here

Filed under: Clinical Trials on January 12th, 2008